Sotatercept offers a new treatment option for adults with pulmonary arterial hypertension by targeting vascular signaling involved in disease progression.
Article Highlights
- Sotatercept represents the first new mechanistic pathway in pulmonary arterial hypertension (PAH) management in over a decade, shifting beyond the established endothelin, prostacyclin, and nitric oxide axes.
- The agent functions as a signaling inhibitor that rebalances pulmonary vascular homeostasis toward an anti-proliferative state.
- Across phase II (PULSAR) and phase III (STELLAR) studies, Sotatercept demonstrated consistently positive results, culminating in FDA approval. This translational trajectory underscores both the reproducibility of clinical benefit and the emerging role of this therapy as an adjunct to background regimens, with early indications suggesting potential reversal of vascular pathology.
On March 26, 2024, Merck announced the FDA approval of their new drug, sotatercept (brand name Winrevair), for the treatment of pulmonary arterial hypertension (PAH) in adults.
The 45-60 mg injection, given once every three weeks by a health care professional, allows individuals with PAH to increase exercise capacity, improve lung function and reduce the risk of clinically worsening events.
Sotatercept, the first new therapy for PAH in over a decade, is the first approved activin signaling inhibitor therapy, a new class of drugs that work by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.
In the video above, Dr. Zeenat Safdar, a pulmonologist and professor of medicine at Houston Methodist Hospital, discusses her role in the research leading to the FDA approval of sotatercept and its primary benefits to patients.
Pulmonary arterial hypertension is a progressive, life-threatening disease that causes blood vessels in the lungs to thicken and narrow, causing significant strain on the heart.
In a series of clinical trials, Dr. Safdar and colleagues determined that sotatercept demonstrated significant clinical benefits when added to existing PAH therapy. It allowed patients to walk significantly further in six-minute tests than their baseline without sotatercept and substantially reduced their risk of death from any cause.
"Sotatercept is an activin signaling molecule that rebalances the lung vasculature to a more anti-proliferative rather than a proliferative state, so there's less growth and more apoptosis among the cells that cause the disease," Dr. Safdar explained. "This is an important breakthrough that looks like it may help reverse the disease process for these patients."
Transcript
00:00–00:30
I'm very excited about this novel compound called Sotatercept. It is a new medication. I've been involved in the clinical trials from the very beginning. Starting with a phase two study PULSAR, to the phase three study STELLAR, and now the phase four open label study called SOTERIA. My name is Dr. Zeenat Safdar. I'm Professor of Medicine at Houston Methodist. I have been involved in pulmonary hypertension research for the last 20 years. It has been several, several years,
00:30–01:00
I would say more than 14 years since the last time a new pathway was identified and targeted and proven beneficial for our patients. Right now there are about 14 medications available to treat pulmonary arterial hypertension. These medications basically target three pathways, the endothelin pathway, the prostacyclin pathway, and the nitric oxide pathway. So this is a new pathway that, that potentially will be able to add on background therapy for these patients and we’ll be able to modify the disease process itself.
01:00–01:30
This new molecule that we were studying for the last several years is an active and signaling molecule. It's an active and signaling inhibitor that rebalances the lung vasculature to a more anti-proliferative rather than a proliferative state. So there's less growth of these cells and there's more apoptosis so that the vessel wall regains its normal balance that is lost in the disease process.
01:30–02:00
The phase two study was very promising. The results were very positive. The phase three study was very positive. So it's very exciting that a new drug has been approved by the FDA to treat pulmonary arterial hypertension. It looks like it's going to help to reverse the disease process in the lung vasculature and reverse the vascular remodeling that's happening and ongoing in this patients.